Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
C. Landi (Siena, Italy), P. Cameli (Siena, Italy), L. Bergantini (Siena, Italy), M. D'Alessandro (Siena, Italy), L. Bianchi (Siena, Italy), E. Shaba (Siena, Italy), P. Rottoli (Siena, Italy), L. Bini (Siena, Italy), E. Bargagli (Siena, Italy)
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Session: Innovations in idiopathic pulmonary fibrosis
Session type: Thematic Poster
Number: 1328
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Landi (Siena, Italy), P. Cameli (Siena, Italy), L. Bergantini (Siena, Italy), M. D'Alessandro (Siena, Italy), L. Bianchi (Siena, Italy), E. Shaba (Siena, Italy), P. Rottoli (Siena, Italy), L. Bini (Siena, Italy), E. Bargagli (Siena, Italy). Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach. 1328
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: